Treatment of Sarcoidosis in U.S. Rheumatology Practices: Data from ACR's Rheumatology Informatics System for Effectiveness (RISE) Registry.

Nevin HammamMichael EvansEsi M MorganAndreas ReimoldChristine AnastasiouJulia L KayRebecca Grainger Gabriela Schmajuk

Published in: Arthritis care & research (2020)

In a large sample of U.S. rheumatology practices, 12.1% of patients with sarcoidosis received biologics or tsDMARD. We found high variability in biologic use across practices. The significant use of long-term glucocorticoids suggests unmet therapeutic needs in this patient population.

Keyphrases

primary care
healthcare
juvenile idiopathic arthritis
electronic health record
rheumatoid arthritis
randomized controlled trial
big data
systematic review
case report
machine learning